From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Routes of
Pharmacokinetic data
Biological half-life 5 days (mean)
CAS Number 443913-73-3
ATC code none
PubChem CID 3081361
Chemical data
Formula C22H24BrFN4O2
Molar mass 475.354 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR)[1]. It is a tyrosine kinase inhibitor.

Drug has a third target: inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer

Current status

Vandetanib is being developed by AstraZeneca. It is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. There have been some promising results from a phase III trial with docetaxel[2]. There have also been ambivalent results when used with pemetrexed[3] Another trial with docetaxel was recruiting in July 2009[4]. AstraZeneca withdrew regulatory submissions for Zactima in October 2009 after trials showed no benefit when the drug was administered alongside chemotherapy [5].

External links


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  2. "Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer" June 2009
  3. "IASLC: Vandetanib Fails to Improve NSCLC Outcomes with Pemetrexed" Aug 2009
  5. "AstraZeneca drops after it withdraws submissions for cancer drug"